Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 2/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 2/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5752352 | 0.92 | UGCG (0.52) | UGCGFFAR2POLBRAB9ASMN1; SMN2 | |
| SCHEMBL5753708 | 0.85 | NOS3 (0.43) | UGCGSMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL5752726 | 0.84 | UGCG (0.41) | UGCGFFAR2NOS3NOS1NOS2 | |
| SCHEMBL5750265 | 0.83 | UGCG (0.41) | UGCGFFAR2POLBRAB9ASMN1; SMN2 | |
| SCHEMBL5753157 | 0.83 | UGCG (0.41) | UGCGFFAR2POLBRAB9ASMN1; SMN2 | |
| SCHEMBL5752644 | 0.82 | NOS3 (0.42) | UGCGSMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL5751360 | 0.82 | NOS3 (0.42) | UGCGFFAR2SMN1; SMN2NOS3NOS1 | |
| SCHEMBL5753673 | 0.81 | FFAR2 (0.52) | UGCGFFAR2 | |
| SCHEMBL5752076 | 0.80 | NOS3 (0.44) | UGCGNOS3NOS1NOS2TACR1 | |
| SCHEMBL6580474 | 0.80 | NOS3 (0.44) | UGCGNOS3NOS1NOS2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | UGCG 740/4885FFAR2 184/4885POLB 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.